EA201690731A1 - Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах - Google Patents

Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах

Info

Publication number
EA201690731A1
EA201690731A1 EA201690731A EA201690731A EA201690731A1 EA 201690731 A1 EA201690731 A1 EA 201690731A1 EA 201690731 A EA201690731 A EA 201690731A EA 201690731 A EA201690731 A EA 201690731A EA 201690731 A1 EA201690731 A1 EA 201690731A1
Authority
EA
Eurasian Patent Office
Prior art keywords
analysis
igfbp7
improved characteristics
biological specimens
improved
Prior art date
Application number
EA201690731A
Other languages
English (en)
Russian (ru)
Inventor
Рави А. Виджаендран
Сриватса Венкатасуббарао
Original Assignee
Астьют Медикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астьют Медикал, Инк. filed Critical Астьют Медикал, Инк.
Publication of EA201690731A1 publication Critical patent/EA201690731A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EA201690731A 2013-11-06 2014-11-06 Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах EA201690731A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900942P 2013-11-06 2013-11-06
US201462054324P 2014-09-23 2014-09-23
US201462064380P 2014-10-15 2014-10-15
PCT/US2014/064327 WO2015069880A1 (en) 2013-11-06 2014-11-06 Assays for igfbp7 having improved performance in biological samples

Publications (1)

Publication Number Publication Date
EA201690731A1 true EA201690731A1 (ru) 2016-10-31

Family

ID=53042071

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690731A EA201690731A1 (ru) 2013-11-06 2014-11-06 Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах

Country Status (12)

Country Link
US (3) US9822172B2 (enExample)
EP (2) EP3066221A4 (enExample)
JP (4) JP2017501211A (enExample)
KR (1) KR102404285B1 (enExample)
CN (1) CN105793439B (enExample)
AU (1) AU2014346695B2 (enExample)
BR (1) BR112016010106A2 (enExample)
CA (2) CA3185700A1 (enExample)
EA (1) EA201690731A1 (enExample)
HK (1) HK1221490A1 (enExample)
MX (1) MX375701B (enExample)
WO (1) WO2015069880A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106370857A (zh) 2008-10-21 2017-02-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
BR112017005554A2 (en) * 2014-10-29 2018-01-23 F. Hoffmann-La Roche Ag methods for predicting a subject's risk of rapid progression to chronic heart failure and uses of at least one biomarker and at least one binding agent
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2774967T3 (es) * 2015-10-08 2020-07-23 Hoffmann La Roche IGFBP7 para la predicción del riesgo de LRA cuando se mide antes de una intervención quirúrgica
CN109844526A (zh) 2016-06-06 2019-06-04 机敏医药股份有限公司 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3606554A4 (en) 2017-04-05 2020-12-09 Astute Medical, Inc. ASSAYS FOR TIMP2 WITH IMPROVED EFFICIENCY IN BIOLOGICAL SAMPLES
CA3101470A1 (en) 2018-05-24 2019-11-28 Renibus Therapeutics, Inc. Methods of treating patients at risk for renal injury and renal failure
WO2020234482A1 (en) * 2019-05-21 2020-11-26 Universität Zürich MAPKi RESISTANCE SIGNATURES
KR102533791B1 (ko) * 2022-09-15 2023-05-18 경북대학교 산학협력단 비색법 신호형질 복합체, 이를 이용하는 신장질환 진단용 키트 및 진단법
EP4729541A1 (en) * 2024-10-16 2026-04-22 Paolo Fiorina Anti- igfbp7 antibodies and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3029579C2 (de) 1980-08-05 1985-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Mittel zur Abtrennung von Plasma oder Serum aus Vollblut
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5166051A (en) 1990-08-08 1992-11-24 Genesis Labs, Inc. Membranes, membrane overlays for exclusion of erythrocytes, and method for immunoassay of whole blood analytes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6391265B1 (en) 1996-08-26 2002-05-21 Biosite Diagnostics, Inc. Devices incorporating filters for filtering fluid samples
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6045899A (en) 1996-12-12 2000-04-04 Usf Filtration & Separations Group, Inc. Highly assymetric, hydrophilic, microfiltration membranes having large pore diameters
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US7109030B2 (en) * 2000-03-31 2006-09-19 Nuvelo, Inc. Methods of therapy and diagnosis using insulin-like growth factor binding protein-like polypeptides and polynucleotides
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
WO2006119203A2 (en) * 2005-04-29 2006-11-09 Beckman Coulter Fluorescence lateral flow immunoassay
CA2902070A1 (en) * 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
EP2498095A3 (en) * 2007-01-25 2012-11-28 Roche Diagniostics GmbH Use of IGFBP-7 in the assessment of heart failure
CA2740134C (en) * 2008-10-14 2021-10-26 National Research Council Of Canada Formulations targeting igfbp7 for diagnosis and therapy of cancer
MX2011011670A (es) 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CA2788826C (en) 2010-02-05 2023-09-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130224191A1 (en) * 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
KR20140091038A (ko) * 2011-11-03 2014-07-18 톨러러 세러퓨틱스 인코포레이티드 T-세포 반응의 선택적 억제를 위한 항체 및 방법

Also Published As

Publication number Publication date
AU2014346695A1 (en) 2016-06-16
KR20160068988A (ko) 2016-06-15
EP3556863A1 (en) 2019-10-23
JP2020048569A (ja) 2020-04-02
MX2016005834A (es) 2016-11-17
US10562961B2 (en) 2020-02-18
KR102404285B1 (ko) 2022-05-31
BR112016010106A2 (pt) 2017-12-05
CA2929547C (en) 2023-02-28
HK1221490A1 (zh) 2017-06-02
WO2015069880A1 (en) 2015-05-14
US20160289308A1 (en) 2016-10-06
MX375701B (es) 2025-03-06
AU2014346695B2 (en) 2020-10-15
JP7277623B2 (ja) 2023-05-19
US9822172B2 (en) 2017-11-21
CA3185700A1 (en) 2015-05-14
CN105793439A (zh) 2016-07-20
JP2023052239A (ja) 2023-04-11
CA2929547A1 (en) 2015-05-14
US20200247879A1 (en) 2020-08-06
US20180066045A1 (en) 2018-03-08
JP2022068143A (ja) 2022-05-09
EP3066221A4 (en) 2017-09-20
EP3066221A1 (en) 2016-09-14
EP3556863B1 (en) 2024-09-18
JP2017501211A (ja) 2017-01-12
CN105793439B (zh) 2020-09-04

Similar Documents

Publication Publication Date Title
EA201690185A1 (ru) Анализ timp2, обладающий улучшенной эффективностью в биологическом образце
MX2016005834A (es) Ensayos para igfbp7 con mejor rendimiento en muestras biológicas.
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
CL2015002756A1 (es) Moléculas fc biespecíficas
MX377956B (es) Sistemas y métodos para maximización de uso de muestras.
BR112015022490A2 (pt) métodos e composições para classificação de amostras
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
BR112015007672A2 (pt) anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
WO2014144822A3 (en) Methods and compositions for tagging and analyzing samples
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
EP2953643A4 (en) NON-PLATE DEPLETING AND NON-ERYTHROCYTE DEPLETING CD47 ANTIBODIES AND METHOD FOR USE THEREOF
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
EA201491599A1 (ru) Антитела к матриксной металлопротеиназе 9
MX377772B (es) Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos.
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
MX362075B (es) Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
EA201890078A1 (ru) Антитело
EA201792289A1 (ru) Способы обнаружения агглютинации и композиции для их осуществления
IN2014DN08011A (enExample)
EA201400873A1 (ru) Механическая промывка и измерительный прибор для выполнения анализов
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов